The prodrug capecitabine (Xeloda) has been an important drug for treatment for gastrointestinal cancer (GI-cancer). This study explores the efficacy of continuous metronomic Xeloda, as well as tolerability and best response during treatment. Patients (n=35) with stage IV GI-cancer were included in the study and were divided into two groups; upper (n=13) and lower (n=22) GI-cancer. All patients ...

Background: Metastatic gastrointestinal cancer (GI-cancer) is often a chronic disease where the treatment intention often is palliative. For such patients, it is important to offer treatments that can prevent tumor progression without reducing quality of life more than necessary. Metronomic chemotherapy involves continuous administration of cytostatic drugs at low doses without longer drugfree ...

  Background and Objectives: To compare pathologic complete response (pCR) in patients with advanced rectal cancer receiving neoadjuvant chemoradiotherapy (NACT) by 5-FU or Xeloda (capecitabine) with and without Eloxatin (oxaloplatin injection). Materials and Methods: Seventy-five consecutive patients with the diagnosis of advanced rectal adenocarcinoma were included. Two basic chemotherapy r...

Both paclitaxel and docetaxel are mitotic inhibitors with similar mechanisms of action. In our patient, CME was thought to be secondary to paclitaxel use. Paclitaxel treatment was discontinued and capecitabine (Xeloda; Hoffman-LaRoche Inc, Nutley, NJ) was prescribed by the patient’s oncologist. Six weeks after cessation of paclitaxel treatment, the patient’s bestcorrected visual acuity improved...

Capecitabine (Xeloda®) is an oral prodrug that is converted to 5-fluorouracil (5-FU) in a three-step enzymatic process, the final stage of which is mediated by thymidine phosphorylase (TP). Significantly higher TP activity has been recorded in a number of human tumour tissues (including colorectal, breast, stomach, cervix, uterus, ovary, kidney, bladder, and thyroid), compared with normal tissu...